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Abstract. Ocular toxocariasis can be vision threatening, and is commonly reported from tropical or subtropical
regions. Knowledge of clinical manifestations from the United States, particularly in underserved areas such as the
American South, is lacking. We report three cases of ocular toxocariasis in individuals from the Mississippi Delta, a rural
community with prevalent poverty. Visual acuity was severely affected in two of the three cases. Increased awareness of
ocular toxocariasis, which may have under-recognized frequency, will contribute to prompt diagnosis and treatment,
which will ultimately improve patient health in the region.
INTRODUCTION
Toxocariasis is caused by larvae of Toxocara canis, or
Toxocara cati, intestinal nematodes infecting dogs and cats,
respectively. Toxocariasis ismore commonly found in tropical
and subtropical regions.1 Infection in the definitive hosts is
acquired via ingestion of larvated eggs in the soil or of in-
cidental hosts, such as birds or rodents, infected with the
larval stage of the parasite.2 Humans acquire Toxocara larva
migrans disease by accidental ingestion of larvated eggs.
Toxocara larvae may migrate through the body, causing vis-
ceral larva migrans (VLM), neural larva migrans, and ocular
toxocariasis, or ocular larva migrans (OLM).3 Visceral larva
migrans is characterized by fever, hepatomegaly, respiratory
symptoms, and eosinophilia, although infection may be
asymptomatic.4 By contrast, OLM is vision threatening,5,6
often accompanying VLM, although isolated OLM without
visceral involvement occurs.
In the United States, recent studies have shown a 5%
Toxocara antibody seroprevalence in the general population.7
Most studies to date in the United States have evaluated ep-
idemiologic aspects of toxocariasis based on Toxocara anti-
body seroprevalence, but knowledge of clinical manifestation
frequency, particularly in underserved and understudied
populations such as the American South, is lacking. Here, we
report three cases of OLM in individuals from Mississippi,
specifically from the Mississippi Delta.
CASE REPORTS
Case 1. A 25-year-old, non-Hispanic, Caucasian female
presented with a 6-month history of floaters and worsening
vision inher right eye.Herocular symptomswereaccompanied
by headache, nausea,malaise, andpalpitations. She had lived
in the state of Mississippi for the entire life, and had no pets or
recent travel.
Ophthalmologic examination of the right eye revealed visual
acuity of 20/70 and normal intraocular pressure. Anterior-
segment examination showed a posterior subcapsular cata-
ract. Posterior-segment examination showed a large focal
granulomatous chorioretinitis along the supratemporal arcade
with vitritis (Figure 1A), with inferior snowbanking (accumula-
tion of vitreous exudates), macular striae, and small retinal
membranes. No larvae were visualized. The left eye was nor-
mal (Figure 1B). Laboratory evaluation for antinuclear anti-
body, angiotensin-converting enzyme (ACE), syphilis, Lyme,
Toxoplasma, Rocky Mountain spotted fever, and human leu-
kocyte antigen-B51, and Toxocara antibody testing by ELISA
was negative. Magnetic resonance imaging of the brain and
orbits showed no abnormalities. Empiric intravitreal clinda-
mycin injection was administered for possible Toxoplasma
chorioretinitis without improvement. Pars plana vitrectomy for
vitreous biopsy and cataract extraction with intraocular lens
placement, as well as corticosteroid injection to control the
inflammation, were performed. Topical ophthalmic cortico-
steroid therapy was also initiated. Toxocara ELISA performed
on a vitreous sample was positive. The patient was then re-
ferred to an infectious disease specialist to rule out VLM.
On further evaluation, physical examination was benign. Her
laboratory tests indicated white blood cell count of 8.7 × 109/L
with 2.1% eosinophils, and liver transaminases were normal.
Electrocardiogram and echocardiogram were normal. Com-
puted tomography of the chest, abdomen, and pelvis revealed
small mesenteric lymphadenopathy and a normal chest. Given
the negative ACE and chest X-ray, and as she was Caucasian,
sarcoidosis was considered to be a less likely diagnosis. A di-
agnosis of OLM was made based on the positive vitreous an-
tibody and the characteristic findings of a focal elevated lesion
consistent with choroidal granuloma in the posterior pole of the
right eye and vitritis. She was treated with oral albendazole
(400 mg twice daily for 2 weeks) and continued on ophthalmic
corticosteroid drops. She developed elevated intraocular
pressures requiringplacementof anaqueous tubeshuntaswell
as cystoid macular edema, which severely compromised her
visual acuity. Three years later, her visual acuity permits
counting fingers at 3 feet, without improvement on pinhole
examination. She continues topical corticosteroid treatments.
Case 2. A 22-year-old, non-Hispanic, Caucasian male
presented with poor vision in his right eye. The patient
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reported hewas told that he hada “tumor”behind the right eye
at age 5 years, which left him nearly blind in that eye. The
patient deniedeyepain andheadaches.Hehadbeena lifelong
resident of theMississippi state, andstraydogswere common
in the area in which he was raised. There was no recent travel.
Ophthalmologic examination revealed a visual acuity that
permitted detection of hand motion in the right eye and 20/20
with correction in the left eye. Intraocular pressures were
normal in both eyes. Anterior-segment examination was nor-
mal bilaterally. Posterior-segment examination of the right eye
showed a white-yellow, subretinal vermiform lesion elevating
peripapillary retina consistentwith granulomas supratemporal
to the optic disc (Figure 2A). The retinal pigment epithelium
was atrophied, and retinal striae were observed extending
from the optic disc to the fovea. No larvaewere visualized. The
left eye examination was normal (Figure 2B). Based on the
fundoscopic examination that showed characteristic lesion
consistent with granulomas, a clinical diagnosis of OLM was
made. The treating ophthalmologists considered that the
findings were consistent with OLM but not with other condi-
tions that are accompanied by granulomas in the eyes based
on the characteristic focal elevated granulomas of the pos-
terior pole and a pigmented crescentic or vermiform shape
within the elevated granuloma or scar (Figure 2), which is
highly suggestive of a dead larva.
Because the infection was determined to be only ocular,
and not active, no intervention was performed. Further ex-
aminations to evaluate for sarcoid, syphilis, Mycobacterium
tuberculosis, toxoplasmosis, and toxocariasis were not con-
ducted as the patient was lost to follow-up.
Case 3. A 5-year-old, non-Hispanic, Caucasian male who
lived in the Mississippi Delta presented with blurred vision in
the left eye. The patient had no pets, but did have contact with
neighborhood dogs. The patient had no travel history.
Ophthalmologic examination showedanuncorrected visual
acuity of 20/30 in the right eye and 20/150 in the left eye that
improved to 20/80 with pinhole examination. Intraocular
pressures were normal in both eyes. The anterior-segment
examination was normal in both eyes. Fundus examination of
the right eye was normal (Figure 3A). Posterior-segment ex-
amination of the left eye revealed an area of increased pig-
mentation in the superior peripapillary retina extending into the
posterior pole. A fibrotic band and an epimacular membrane
causing substantial distortion of the macula (Figure 3B) were
observed. In addition, a pigmented lesion was observed in the
far peripheral temporal retina (Figure 3C). Therewere no larvae
visualized. ELISA testing for antibody to Toxoplasma and
Toxocara on serum yielded negative results. A clinical di-
agnosis of OLM was made based on the ophthalmologic ex-
amination that showed a characteristic peripheral raised
lesion consistent with a Toxocara granuloma. The patient was
observed without intervention, and the visual acuity of the left
eye improved to 20/40 and 20/25 with correction 6 months
and 2 years later, respectively.
After 5 years of follow-up, the patient had an episode of a
brain abscess requiring craniotomy and prolonged intrave-
nous antibiotic therapy. Abscess culture yielded a Peptos-
treptococcus species, although the patient had received
antibiotics before culture was obtained. Repeat ELISA serol-
ogy for Toxocara remained negative, and further immunologic
workup was negative (HIV testing, quantitative immunoglob-
ulins, and T-cell subsets).
Eight years later, the patient had severe progressive left eye
retinal detachment, requiring barrier laser photocoagulation.
One year after the laser treatment, his visual acuity in the left
eye was 20/20 with correction.
DISCUSSION
We report one highly probable and two likely cases, in-
cluding one pediatric, of OLM from the Mississippi Delta, a
rural community with prevalent poverty. According to the U.S.
Census Bureau, 20.8% of people in Mississippi were living in
poverty in 2014–2016, which reflects the highest rates in the
United States.8 Moreover, because clinical care in this region
is scarce,9 it is likely that more people suffer from this disease
without proper diagnosis and care. This case series illustrates
the fact that ToxocaraOLM still occurs in the American South,
leading to loss of visual acuity and potential blindness in af-
fected individuals.
Recent studies demonstrate higher risk for Toxocara sero-
positivity in rural regions, where sanitation is poor and the
burdenof stray animals is high.10 Indeed, the odds forToxocara
seropositivity are 80–90%higher for those living inpoverty than
for those with incomes greater than the poverty level.7,10 Visual
acuity was severely affected in two of the three cases in our
case series from just such a poverty-affected region. Such loss
of visual acuity resulting from Toxocara leads to long-term re-
duced productivity for those visually impaired persons, con-
tributing further to the cycle of disadvantage.
Ocular larva migrans can manifest in three distinct clinical
forms: focal granulomaof theposterior pole (as seen in the first
and second cases) in 25–50% of patients; peripheral granu-
loma (as seen in the third case, Figure 3) in approximately 50%
of patients; and diffuse endophthalmitis in less than 25% of
cases. In focal granulomas of the posterior pole or the pe-
riphery of the fundus, a pigmented crescentic or vermiform
shape within the granuloma or scar (Figure 2) is highly sug-
gestive of a dead larva.11
Thesecaseshighlight thedifficulty inobtainingadiagnosisof
Toxocara OLM. Although positive serology may be suggestive
of infection, many apparently healthy individuals express de-
tectable serum Toxocara antibody titers. Although one study
has shown 45% of patients with clinically diagnosed OLM
having antibody titers of 1:32 or greater,3 serum antibodies are
not always present in OLM.5,12 Previous reports suggest that
elevation of vitreous fluid antibodies, particularly in the absence
of correspondingly elevated serum antibody titers, as seen in
case 1, is highly suggestive of toxocariasis. However, data for
such interpretations of results are derived from a small number
of cases.Becauseof thehighly invasivenatureofocular sample
collection for testing, diagnosis remains largely based on clin-
ical and ophthalmologic findings.5,13–15 Prompt referral to ex-
perienced ophthalmologists is essential in the context of
suspected Toxocara OLM because of the compromise of vi-
sion.16 Parallel evaluation by infectious disease specialists to
rule out other possible diagnoses is also indicated.
These cases do not necessarily provide examples of opti-
mal treatment. Additional clinical evaluation may have been
useful to exclude other possible causes for the disease
processes for the second case, and the antihelminthic treat-
ment given to the patient in case 1 may not have been in-
dicated. Studies have shown the efficacy of albendazole and
corticosteroid therapy in improving intraocular inflammation
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and preventing recurrences, but current recommendations do
not support the use of antihelminthic therapy in quiescent
disease. Most ophthalmologists see Toxocara-infected pa-
tients in whom the helminth has long since expired in the
choroid or subretinal space, typically in the absence of active
systemic toxocariasis or VLM. For these reasons, there may
be little role for antihelminthics in these patients. On the other
hand, anti-inflammatory therapy is generally accepted as a
part of routine treatment for Toxocara OLM, particularly when
signs of inflammation are evident, and corticosteroids alone
are used to control the intraocular inflammation.16
A recent survey of pediatricians has shown providers have
limited awareness of toxocariasis.17 Patients may also delay
seeking medical help (cases 1 and 2). These cases highlight
the need for increased awareness of human toxocariasis in
areas of potentially higher risk (poverty, rural, and limited
clinical care) in the American South. Increased awareness of
such neglected diseases and their perhaps under-recognized
FIGURE 3. Case 3: A 5-year-old boy with blurry vision OS. (A) The fundus photo of the right eye is unremarkable. (B) The standard-field fundus
photograph shows straightening of the retinal vessels, with temporal dragging of the macular in the left eye. There is a large fibrous band over the
macula. (C) Granulomatous lesion in the far peripheral temporal retina may be appreciated in the montage.
FIGURE 2. Case 2: A 22-year-old man with a history of poor vision in the right eye. (A) The standard-field fundus photograph shows large white-
yellow, posterior pole granulomassuperotemporal to the optic disc. Retinal striae from thedisc to the foveawere identifiedbut arenot clearly seen in
the photograph. (B) The fundus photo of the left eye is unremarkable.
FIGURE 1. Case 1: A 25-year-old woman with floaters in the right eye. (A) The ultra-widefield fundus photograph shows a large focal granuloma
along the superotemporal arcade with vitritis in the right eye. Inferior peripheral granuloma, macular striae, and small retinal membranes were
identified but not clearly seen in the photograph. (B) The fundus photo of the left eye is unremarkable.
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frequency will contribute to prompt diagnosis and treatment,
which will ultimately improve patient health in this region.
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